

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/51672751>

Probing the efficacy of peptide-based inhibitors against acid- and zinc-promoted oligomerization of amyloid- β peptide via single-oligomer spectroscopy

ARTICLE *in* BIOPHYSICAL CHEMISTRY · SEPTEMBER 2011

Impact Factor: 1.99 · DOI: 10.1016/j.bpc.2011.08.006 · Source: PubMed

CITATIONS

8

READS

13

3 AUTHORS, INCLUDING:



Lyndsey R Powell

University of Maryland, College Park

6 PUBLICATIONS 40 CITATIONS

SEE PROFILE

Published in final edited form as:

Biophys Chem. 2012 January ; 160(1): 12–19. doi:10.1016/j.bpc.2011.08.006.

Probing the Efficacy of Peptide-Based Inhibitors against Acid- and Zinc-Promoted Oligomerization of Amyloid- β Peptide via Single-Oligomer Spectroscopy

Lyndsey R. Powell, Kyle D. Dukes, and Robin K. Lammi*

Department of Chemistry, Physics and Geology, Winthrop University, Rock Hill, SC 29733

Abstract

One avenue for prevention and treatment of Alzheimer's disease involves inhibiting the aggregation of amyloid- β peptide (A β). Given the deleterious effects reported for A β dimers and trimers, it is important to investigate inhibition of the earliest association steps. We have employed quantized photobleaching of dye-labeled A β peptides to characterize four peptide-based inhibitors of fibrillogenesis and/or cytotoxicity, assessing their ability to inhibit association in the smallest oligomers ($n = 2-5$). Inhibitors were tested at acidic pH and in the presence of zinc, conditions that may promote oligomerization in vivo. Distributions of peptide species were constructed by examining dozens of surface-tethered monomers and oligomers, one at a time. Results show that all four inhibitors shift the distribution of A β species toward monomers; however, efficacies vary for each compound and sample environment. Collectively, these studies highlight promising design strategies for future oligomerization inhibitors, affording insight into oligomer structures and inhibition mechanisms in two physiologically significant environments.

Keywords

amyloid-beta peptide; soluble oligomers; aggregation inhibitor; acid-induced aggregation; metal-induced aggregation; single molecule spectroscopy

INTRODUCTION

Amyloid- β (A β) is a peptide of 39–43 amino acids that is formed through specific proteolytic cleavage of the transmembrane amyloid precursor protein (APP) [1] and normally circulates in brain plasma and cerebrospinal fluid at pico- to nanomolar concentrations [2]. Although A β monomers may be protective to neurons [3], numerous factors have been shown to promote the peptide's self-association into neurotoxic oligomers and aggregates implicated in Alzheimer's disease (AD; for a review, see ref. [4]). Among the multitude of aggregated species, A β fibrils exhibiting cross- β sheet structure [5, 6] have historically garnered the greatest attention, due to their prevalence in the senile plaques characteristic of AD brain [7–9]. Inhibiting A β fibrillogenesis has been a primary strategy in Alzheimer's drug development. A variety of small molecules [10, 11] and peptides [12] have

© 2011 Elsevier B.V. All rights reserved

*Corresponding Author: Dr. Robin K. Lammi Department of Chemistry, Physics and Geology Winthrop University 101 Sims Science Building Rock Hill, SC 29733 USA Tel: 1.803.323.4946 FAX: 1.803.323.2246 Lammir@winthrop.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

been reported to inhibit fibril formation and/or reduce neurotoxicity of A β aggregates. Successful peptide inhibitors include block copolymers containing recognition and disrupting elements [13, 14], β -sheet breakers employing Pro residues [15, 16], *N*-methylated sequences [17–19], derivatives disubstituted at the α -carbon [20] and sequences containing D-amino acids [19, 21, 22].

Over the last decade, focus has shifted somewhat from the inhibition of fibrillogenesis, as several key results have linked small A β oligomers to the etiology of AD [23]. The accumulation of SDS-stable dimers and trimers [24–27] in the brain is strongly correlated with synapse loss, cognitive impairment and increased severity of end-stage AD [24, 25, 28]. Direct application of cell-derived dimers, trimers and tetramers results in impaired long-term potentiation (LTP) [29–31], short-term memory deficits [32] and synapse loss [33] in rodents. Additionally, A β dimers isolated from the cortex of human AD brain [34] and found in human cerebrospinal fluid [35] inhibit LTP *in vivo*. Collectively, these findings illustrate the crucial role of small A β oligomers in Alzheimer's progression and provide clear incentive to investigate inhibition of A β association in its earliest stages.

Toward that goal, we selected four successful inhibitors of fibrillogenesis and/or neurotoxicity, each with a distinct inhibition strategy (Figure 1) [14, 15, 17, 20], and examined their abilities to prevent or reverse association in the smallest oligomers ($n = 2$ –5). Since oligomers and fibrils have been shown to possess different structures and form through distinct pathways [36], we were interested to determine which compound(s) would most successfully inhibit the earliest association steps. All four inhibitors employ recognition sequences similar to A β 's central hydrophobic region (amino acids 16–21; see Figure 1A) and bind to the full-length peptide via a combination of hydrophobic side-chain interactions and backbone hydrogen bonds [37–40], the atomic-level details of which are not known. KLVFF-K₆ (Figure 1B) contains residues 16–20 of A β with a lysine hexamer as a disrupting element. Murphy and coworkers reported that it significantly alters aggregation kinetics and aggregate morphology while reducing A β cytotoxicity [14, 41, 42]; Moss et al. found that it inhibits monomer aggregation [43]. AMY-1 (Figure 1C) is a peptide analogue of KLVFF-K₆ containing alternating α,α -disubstituted amino acids ($\alpha\alpha$ AA). The Hammer group reported that equimolar concentrations of AMY-1 are highly effective in inhibiting A β fibrillogenesis: while the L-amino acids on one face of the inhibitor permit hydrogen-bonding to A β , steric effects of the $\alpha\alpha$ AA on the other face effectively prevent continued association [20]. A β 16–22m (Figure 1D) also functions by blocking binding of A β on one face of the A β -inhibitor complex, as *N*-methyl amino acids on one side of the inhibitor lack the amide hydrogens used in hydrogen bonding and β -sheet formation [17]. Meredith and colleagues reported that A β 16–22m dramatically inhibits A β fibrillogenesis and successfully dissociates preformed fibrils [17]. Successful inhibition of fibril formation and dissociation of preformed fibrils have also been reported for iA β 5 (LPFFD, Figure 1E), developed by Soto and coworkers; in addition, this inhibitor was shown to prevent A β neurotoxicity [15]. iA β 5 is designed around residues 17–21 of A β : Asp is used in place of Ala-21 for improved solubility, and Pro is substituted in place of Val-18, harnessing the ability of proline to prevent and disrupt β -sheet formation [15, 38].

We tested each of the four inhibitors in Figure 1 against samples of the earliest oligomers, prepared under acidic conditions (pH 5.8) and at physiological pH in the presence of Zn²⁺. These sample environments have been shown to promote A β aggregation [44–49] (and oligomerization [50]) *in vitro* and are also relevant to association *in vivo*. The acidic conditions mimic those of early endosomes where A β is produced [51, 52] and the zinc concentrations used are within the range observed in the brain [53–55], where zinc release during neurotransmission (at concentrations up to 300 μ M [54, 55]) may cause A β oligomers to target synapses [56]. Single-molecule fluorescence spectroscopy was used to

determine distributions of monomers and oligomers present under the various sample conditions, using a method we have reported previously [50] (which was further substantiated by the work of Steel and colleagues [57]). For these measurements, we used A β 40 – the most prevalent form of A β in vivo [58] – that is covalently labeled at the N-terminus with carboxyfluorescein (FAM), and at the C-terminus with Lys-Biotin; this construct is abbreviated FA β B. The peptide is tethered to functionalized cover slips via biotin-streptavidin binding; a dense base layer of polyethylene glycol provides a non-fouling surface, preventing adsorption to the glass [50, 59]. Localized FA β B monomers and oligomers are interrogated, one at a time, through laser excitation. The quantized photobleaching of individual dye molecules permits quantification of the number of associated peptides [50, 57, 60]. By investigating dozens of peptide species, one by one, we have characterized the distributions of monomers and oligomers present under our conditions of interest. We report that all four inhibitors are successful in reducing association in the smallest oligomers, shifting the distribution of FA β B species toward monomers. The variations in efficacy observed for the different compounds in acidic versus zinc-containing samples suggest successful strategies for preventing or reversing the earliest A β association steps and afford new insight into oligomer structures and inhibition mechanisms in two physiologically significant environments.

EXPERIMENTAL METHODS

Materials

FAM-A β 40-Lys-Biotin (FA β B) and iA β 5 (LPFFD) were purchased from AnaSpec, Inc. (Fremont, CA); the remaining three inhibitors (i.e., KLVFF-K₆, AMY-1 and A β 16–22m) were obtained from the Hammer research group, formerly of Louisiana State University. All peptides were stored at –20 °C upon receipt. Zinc(II) chloride (ZnCl₂), sodium chloride (NaCl), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and phosphate buffered saline (PBS) powder were obtained from Fisher. Solutions were prepared in distilled, deionized water (18 M Ω) from a Millipore system. Functionalized cover slips (STREP-01) were purchased from MicroSurfaces, Inc. (Austin, TX). These are pre-coated with a dense layer of polyethylene glycol (PEG), a small percentage of which is functionalized with biotin (surface density $\sim 10^{10}/\text{cm}^2$); the biotin moieties are further bound to streptavidin, each of which has 2–3 accessible sites for binding of biotin-labeled FA β B [61]. Packaged cover slips were stored, vacuum-sealed, at ≤ -20 °C; after opening, unused cover slips were kept in a vacuum desiccator at room temperature, according to the manufacturer's instructions.

Sample Preparation

Phosphate buffered saline (PBS, 1 \times : 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na₂HPO₄, and 1.47 mM KH₂PO₄) and HEPES/NaCl (100 mM HEPES, 50 mM NaCl) buffer solutions were prepared in distilled, deionized water; pH was adjusted as needed with HCl and/or NaOH. Lyophilized FA β B was added to prepared buffer after thawing for 30 minutes; these peptide stock solutions were made at ~ 1 μM concentrations, as determined from spectrophotometry (Beer's Law), using the molar absorptivity of the FAM dye. Additional solutes (e.g., ZnCl₂, inhibitor compounds) were added at this point. Samples were then incubated at room temperature for one hour, after which they were diluted to final FA β B concentrations of approximately 60 pM.

Functionalized cover slips were prepared for use by dragging the bottom, uncoated sides across methanol-moistened lens tissues and edging the top, coated surfaces with Mylar frames (McMaster-Carr), to prevent sample loss. Samples (30–40 μL) were added to the centers of prepared cover slips already in place on the microscope, forming small pools of

solution (area $\sim 1 \text{ cm}^2$), and left for 30 minutes to permit tethering of the biotin-labeled peptides to the streptavidin on the cover slips. At $\sim 60 \text{ pM}$, assuming 100% binding of FA β B monomers to streptavidin, $\sim 0.01\%$ of the available streptavidin binding sites are occupied. Additional buffer solution ($\sim 20\text{-}\mu\text{L}$ aliquots) was added as needed (every ~ 45 minutes) to offset evaporation, which causes higher fluorescence signal and background.

Single-Molecule Fluorescence Spectroscopy

The apparatus used to detect surface-tethered FA β B monomers and oligomers (Figure 2A) was described previously [50]. Briefly, 488-nm light from a krypton-argon laser was focused to a diffraction-limited spot $\sim 300 \text{ nm}$ in diameter by the 100 \times objective (1.3 NA) of an inverted fluorescence microscope. A closed-loop nanopositioning stage raster-scanned samples over the laser spot, exciting surface-tethered peptide species. Fluorescence from excited dyes was collected by the objective, filtered to remove stray laser light (dichroic and holographic notch filters) and detected by an avalanche photodiode (APD) detector. (The $180\text{-}\mu\text{m}^2$ active area of the APD served as a pinhole to approximate confocal imaging.) TTL pulses generated by the APD were detected by a counter/timer board interfaced to custom LabVIEW software.

Samples of surface-tethered FA β B peptides were imaged in $20\times 20\text{-}\mu\text{m}$ regions, generating plots of fluorescence intensity as a function of position; the laser power and scanning rate used ($420\text{--}500 \text{ W/cm}^2$ and $25\text{--}50 \text{ }\mu\text{m/s}$, respectively) were selected to minimize dye photobleaching during imaging. The bright spots detected in each image were examined, one by one, by directing the stage to “park” at each position; emitted photons were counted as a function of time (3- or 5-ms bins) to generate a fluorescence intensity profile for each spot. Excitation was continued until the detected intensity dropped to background levels, as determined from profiles of dark areas. Time-dependent intensity data were typically re-binned to plot counts per 30 ms, allowing for clearer discrimination of signal versus background levels. The number of dyes present in each profile was determined from the number of discrete photobleaching steps observed and the number of distinct intensity levels (at least 100 ms in duration) evident above background. Dozens of bright spots were interrogated for each sample, allowing for the construction of distributions (histograms) of the monomers and oligomers observed. Two-tailed *t*-tests were used to statistically compare oligomer distributions, assuming unequal variances with a confidence interval (α) equal to 0.05.

RESULTS

Single-molecule fluorescence measurements were utilized to assess the efficacy of each inhibitor in preventing or reversing acid- and zinc-promoted oligomerization. For each sample environment, all four peptides were evaluated at 10:1 inhibitor:A β ratios ($\sim 600 \text{ pM}$ inhibitor concentrations); the more promising compounds were further studied at equimolar concentrations ($\sim 60 \text{ pM}$). The distribution of FA β B monomers and small oligomers in a particular sample was constructed by interrogating dozens of spatially resolved peptide species (observed as bright spots in fluorescent images), one at a time, as described previously [50]. Each mono- or oligomer was continuously excited until its emission intensity dropped to a background level; the number of associated peptides was determined from the discrete photobleaching steps observed in the time-dependent fluorescence profile (see Figure 2). Note 1 A monomer exhibits one characteristic fluorescence signal (broadened

¹The number of observed dyes corresponds directly to the number of singly labeled A β peptides in the excited region. As we discussed in ref. 49, under our conditions (i.e., $\sim 10^{10}$ streptavidin per square centimeter of coverslip surface, $\sim 0.01\%$ occupation of streptavidin binding sites by FA β B), we can reasonably assert that the observation of multiple dye-labeled peptides at a single bright spot in a fluorescent image is indicative of oligomerization, rather than binding of several monomers within the focal volume.

by shot noise) from its single dye; the signal drops sharply to background upon dye photobleaching (Figure 2B) [62, 63]. (Brief visits to background intensities may occur prior to irreversible photobleaching, due to intersystem crossing [62, 63], but these “blinks” are rare at our low excitation rates.) A dimer undergoes two photobleaching steps, one for each dye, and therefore exhibits two discrete intensity levels above background (Figure 2C); a trimer shows three intensity levels, and so on. FA β B monomers through pentamers are reliably identified on this basis, as we have demonstrated [50]. Larger oligomers often exhibit smooth, quasi-exponential decays in their intensity profiles, due partly to rapid dye photobleaching, and are more difficult to quantify. Consistent with our earlier findings [50], we observed only a small number of oligomers with $n > 5$, ~2 % of all species for metal-free samples at pH 7.4, ~5 % in the presence of zinc, and ~7 % at pH 5.8. Based on their fluorescence intensities, we estimate that the largest of these oligomers may contain tens of peptides.

Multiple samples were investigated to characterize each set of conditions. Oligomer distributions for replicate samples were found to be highly reproducible (as noted previously [50]); as such, their statistically indistinguishable data sets ($p \gg 0.05$, typically $0.3 < p < 0.9$) were combined to generate composite distributions containing at least 100 individual peptide species. To facilitate comparison across different inhibitors and environments, the composite histograms are depicted below in terms of percentages of monomers and small oligomers.

Inhibiting Association at Acidic pH

Figure 3 depicts distributions of FA β B monomers and small oligomers acquired in PBS buffer at pH 5.8. In the absence of inhibitor, acidic conditions promote increased association over that observed at physiological pH, as shown in panel 3A (and as reported previously [50]). Incubation with 10 molar equivalents of any of the four peptides (Figure 3B) results in a statistically significant shift toward FA β B monomers, as compared to inhibitor-free samples at pH 5.8 ($p \ll 0.01$); however, none of the inhibitors significantly affect the number of unquantifiable larger oligomers, which remains consistent in the absence or presence of inhibitor at ~7 %. Samples containing KLVFF-K₆ and iA β 5 are statistically indistinguishable and exhibit the lowest degree of inhibition. Samples containing AMY-1 reproducibly show the greatest percentage of monomers (85 %); A β 16–22m ranks second in efficacy, producing 61 % monomers.

Composite distributions for AMY-1 and A β 16–22m present at 1 molar equivalent (Figure 3B, inset) are statistically indistinguishable from each other; however, even at this reduced concentration, both inhibitors successfully shift the distribution of observed FA β B species toward monomers ($p \ll 0.01$ compared to inhibitor-free samples). Inhibition by A β 16–22m is apparently unaffected by concentration changes in this range, as the distributions for 1 and 10 equivalents of this inhibitor are statistically indistinguishable ($p = 0.37$). AMY-1 is significantly less effective when present at one versus ten molar equivalents ($p < 0.01$).

Inhibiting Association in the Presence of Zinc

The addition of 4 molar equivalents of Zn²⁺ at pH 7.4 promotes increased oligomerization over that observed for metal-free samples, as shown in Figure 4A (and reported previously [50]). As observed under acidic conditions, incubation with 10 molar equivalents of any of the four peptides results in a statistically significant shift toward FA β B monomers (Figure 4B), as compared to inhibitor-free samples in the presence of zinc ($p \ll 0.01$). Under these conditions, A β 16–22m and KLVFF-K₆ are most successful in reducing oligomerization; distributions for these two inhibitors are statistically indistinguishable from each other, but show significantly improved inhibition over AMY-1 or iA β 5. In fact, inhibition by A β 16–

22m or KLVFF-K₆ in the presence of zinc is comparable to that afforded by the zinc chelator clioquinol, reported previously [50]: FA β B oligomer distributions are statistically indistinguishable, with 64, 58, and 54 % monomers for samples containing ten equivalents of A β 16–22m, KLVFF-K₆, and clioquinol, respectively. The presence of inhibitor in zinc-containing samples also seems to reduce the percentage of larger FA β B oligomers ($n > 5$), from ~5 % in inhibitor-free samples to ~4 % (iA β 5), ~3 % (AMY-1, KLVFF-K₆), or ~1 % (A β 16–22m).

At one molar equivalent (Figure 4B, inset), both A β 16–22m and KLVFF-K₆ again cause a significant shift of FA β B species toward monomers ($p \ll 0.01$ compared to the inhibitor-free distribution in Figure 4A); however, the two compounds cannot be distinguished in terms of efficacy. The effectiveness of A β 16–22m is somewhat decreased from that observed with 10 equivalents of the peptide ($p < 0.01$), demonstrating a concentration-dependent response, whereas the distribution for KLVFF-K₆ at one equivalent cannot be distinguished from that observed when the inhibitor is present in excess ($p = 0.28$).

Evaluating Inhibitor Consistency in Different Sample Environments

Statistical comparison of the histograms in Figures 3B and 4B confirms that oligomer distributions for A β 16–22m-containing samples at pH 5.8 and in the presence of zinc are indistinguishable ($p = 0.77$ for 10 equivalents of inhibitor); the same is true for distributions obtained in the presence of iA β 5 ($p = 0.68$). In contrast, comparison of oligomer distributions for AMY-1- or KLVFF-K₆-containing samples verifies statistically significant differences for acidic versus zinc-containing environments ($p < 0.01$).

DISCUSSION

A number of recent studies have linked A β dimers and trimers to symptoms of Alzheimer's disease, including synapse loss, short-term memory deficits and LTP impairment [29–35], providing clear incentive to identify inhibitors of the earliest A β association steps. Further, since the earliest A β oligomers may be found in acidic endosomes where A β is produced [51, 52] and recruited to synapses by zinc release during neurotransmission [56], inhibiting oligomerization in acidic and zinc-containing environments is of particular interest. Through single-oligomer spectroscopy, we have successfully characterized the efficacies of four peptides with distinct inhibition strategies, determining distributions of monomers and small oligomers in each of these environments. To our knowledge, these are some of the first empirical studies to investigate inhibition of the earliest oligomerization steps in the presence of acid or zinc.

The inhibition of FA β B oligomerization exhibited by all four peptides, particularly when present at equimolar concentrations (also observed for iA β 5 under at pH 5.8; data not shown) reveals that these molecules successfully bind to small oligomers and/or monomers and shift the equilibrium [64] of oligomeric species toward smaller assemblies. Recognition may be facilitated by β -character in the central hydrophobic region of the full-length peptides and the presence of a turn and/or salt bridge around residues 23–28, common features of the fibrils these compounds are designed to bind [65] which have recently been discovered in simulations of A β monomers and small oligomers [66–69].

Although the most effective inhibitors in each sample environment afford a 5- to 8-fold increase in the percentage of FA β B monomers over that observed for inhibitor-free samples, the efficacies of individual compounds vary significantly in acidic versus metal-containing environments (Figures 3 and 4). These variations highlight the most successful strategies for inhibition of acid- versus zinc-promoted oligomerization and inform on the nature of acidic versus zinc-containing oligomers. We recognize that our results for FA β B do not

specifically inform on association of native A β 40. However, they should afford a few insights regarding the inhibition of oligomerization in these important sample environments, given that fluorophore attachment at the N-terminus has been shown to preserve the biological activity of A β , including fibril morphology [57], binding to senile plaques [70], neurotoxicity [71] and membrane permeability [57].

Under acidic conditions, the two most successful oligomerization inhibitors possess similar structural motifs and inhibition strategies. AMY-1 (Figure 1C) and A β 16–22m (Figure 1D) differ significantly in terms of net charge and hydrophobic/hydrophilic character, as the latter lacks the hexalysine disrupting element; however, both peptides adopt β -strand secondary structure [17, 20] (confirmed at pH 5.8; data not shown), unlike the less effective iA β 5 and KLVFF-K₆ [42] compounds. In addition, once bound, AMY-1 and A β 16–22m both use substituents on one face of the peptide to block further association: the bulky α , α -groups in AMY-1 sterically prevent the close approach of neighboring chains, while the *N*-methyl groups in A β 16–22m prevent hydrogen bonding. These commonalities in structure and design may be key factors for successful inhibition of the earliest association steps under acidic conditions. Interestingly, molecular dynamics simulations on A β peptides at pH 6 showed that acidic conditions cause increased β -character and increased solvent accessibility in the central hydrophobic region [72], which may lead to improved A β recognition by β -structured inhibitors such as AMY-1 and A β 16–22m.

In the presence of zinc at physiological pH, the two most effective peptide inhibitors, A β 16–22m and KLVFF-K₆, exhibit equal capability to prevent or reverse the earliest A β association steps (Figure 4B), but share few other commonalities. A β 16–22m is β -structured [17] and primarily hydrophobic, with a net charge of +1; in contrast, KLVFF-K₆ is unstructured [42] and highly charged (net +8), with distinct hydrophobic and hydrophilic regions (Figure 1).Note 2 In terms of inhibition strategy, while A β 16–22m utilizes its *N*-methyl groups to prevent association on one face of the peptide, as discussed above, KLVFF-K₆ uses a lysine hexamer to disrupt association electrostatically. Cairo et al. proposed that electrostatic interactions between these lysine residues and the Glu-22 and Asp-23 residues of A β also stabilize inhibitor binding, permitting superior recognition of small A β oligomers at physiological pH [73]. In the current studies, the increased positive charge on oligomers containing bound zinc ions may further improve the disruption capability of the oligolysine unit.

The observation that three very different inhibitors – A β 16–22m, KLVFF-K₆, and clioquinol (studied previously [50]) – are equally successful in combating the first stages of zinc-promoted association suggests that zinc-containing oligomers may be more weakly associated and/or more structurally diverse than those formed at pH 5.8. The same is apparently true for assemblies containing tens of associated peptides: whereas none of the four inhibitors successfully reduce the percentage of larger oligomers ($n > 5$) at pH 5.8, all of them apparently decrease the prevalence of these species in zinc-containing samples. These findings are also consistent with reports from several groups, which suggest that A β oligomers containing zinc appear looser and are more easily dissociated than those without coordinated metal ions [47, 74, 75].Note 3

²Circular dichroism spectra of AMY-1 and KLVFF-K₆ in acidic and zinc-containing environments match those reported for metal-free samples at physiological pH (data not shown).

³In light of the rather broad success for inhibition of zinc-promoted oligomerization, it is perhaps surprising that AMY-1 demonstrates only mild efficacy in this environment, significantly lower than that exhibited at pH 5.8. Given the superior effectiveness of A β 16–22m, which has similar secondary structure and inhibition strategy, and KLVFF-K₆, which contains the same hexalysine disrupting element, we speculate that AMY-1's bulky α -substituents hinder the approach of AMY-1 to FA β B oligomers in the presence of zinc more so than they do at acidic pH.

Despite these apparent variations in oligomer structure, the efficacies of two of the four inhibitors are basically unaffected by the different environments. We attribute the limited efficacy of iA β 5 to less successful recognition of FA β B oligomers and suggest that its “ β -sheet-breaker” inhibition strategy is better suited to targeting fibrils with well-defined cross- β structure, as opposed to the early oligomers investigated here. This inference is qualitatively consistent with previous *in vitro* studies of A β oligomers: Hoshi et al. reported that iA β 5 does not inhibit formation of spherical oligomers [76], while Cairo et al. found that it does not bind to the small A β (10–35) assemblies used in their SPR studies [73].

In contrast to iA β 5, A β 16–22m exhibits superior efficacy against the earliest assemblies in both acidic and zinc-containing samples, due to highly successful recognition of full-length peptides in both environments. (Affinity is somewhat greater for acidic versus zinc-containing species, as evidenced by the concentration-independent inhibition observed at pH 5.8.) Molecular dynamics simulations of A β 16–22m and A β 16–20m (in which Leu-17 and Phe-19 are *N*-methylated) revealed that the extended, β -strand conformations of the inhibitors greatly facilitated binding to small, β -structured A β 16–22 assemblies, due to reduced entropic costs [77, 78]. The same reasoning likely applies here, since acidic conditions (pH 6) [72] and zinc binding [79] are reported to increase the β -character in the central hydrophobic (recognition) region of the full-length peptide. Simulations also suggest that the inhibitor's rather rigid, extended structure permits it to intercalate between peptide strands (in addition to binding modes preventing lateral and longitudinal association), facilitating the removal of associated peptides [77, 78].

CONCLUSIONS

In summary, we have evaluated four peptide inhibitors of A β fibrillogenesis based on their abilities to inhibit acid- and zinc-promoted oligomerization physiologically relevant conditions. Single-oligomer fluorescence measurements on FA β B species revealed that all four inhibitors successfully combat the earliest association steps in both acidic and zinc-containing environments. The most successful inhibitors at pH 5.8, AMY-1 and A β 16–22m, are β -structured, with blocking substituents on one face of the peptide. In the presence of zinc, the disparate inhibition strategies employed by A β 16–22m, KLVFF-K₆ and the zinc chelator clioquinol are equally effective, suggesting that zinc-containing oligomers may be looser and/or more structurally diverse. The *N*-methylated inhibitor A β 16–22m is most successful across both sample environments, likely due to its rather rigid, extended conformation, which is expected to facilitate recognition and permit intercalation between associated peptides.

Acknowledgments

We gratefully acknowledge support from the National Science Foundation (NSF CHE-0848824) and the National Center for Research Resources (NIH P20 RR-016461), in addition to the Winthrop University Research Council. We also thank Dr. Robert Hammer for providing three of the inhibitors studied.

REFERENCES

1. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. *Nature*. 1987; 325:733–736. [PubMed: 2881207]
2. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher MG, Whaley J, Swindlehurst C, McCormack R, Wolfert R, Selkoe DJ, Lieberburg I, Schenk D. Isolation and quantitation of soluble Alzheimer's β -peptide from biological fluids. *Nature*. 1992; 359:325–327. [PubMed: 1406936]


3. Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V, Molinaro G, Pappalardo G, Messina A, Palmigiano A, Garozzo D, Nicoletti F, Rizzarelli E, Copani A. The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology. *J. Neurosci.* 2009; 29:10582–10587. [PubMed: 19710311]
4. Lazo, ND.; Maji, SK.; Fradinger, EA.; Bitan, G.; Teplow, DB. Amyloid proteins: The beta-sheet conformation and disease. Sipe, J., editor. Vol. vol. 2. Wiley-VCH; Weinheim, Germany: 2005. p. 385-491.
5. Eanes ED, Glenner GG. X-ray diffraction studies on amyloid filaments. *J. Histochem. Cytochem.* 1968; 16:673–677. [PubMed: 5723775]
6. Bonar L, Cohen AS, Skinner MM. Characterization of the amyloid fibril as a cross- β protein. *Proc. Soc. Exp. Biol. Med.* 1969; 131:1373–1375. [PubMed: 5812002]
7. Glenner GG, Wong CW. Alzheimer disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. *Biochem. Biophys. Res. Commun.* 1984; 122:1131–1135. [PubMed: 6236805]
8. Masters CL, Simms G, Weiman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc. Natl. Acad. Sci. USA.* 1985; 82:4245–4249. [PubMed: 3159021]
9. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science.* 1992; 256:184–185. [PubMed: 1566067]
10. DaSilva KA, Shaw JE, McLaurin J. Amyloid- β fibrillogenesis: structural insight and therapeutic intervention. *Exp. Neurol.* 2010; 223:311–321. [PubMed: 19744483]
11. LeVine H III. Small molecule inhibitors of A β assembly. *Amyloid.* 2007; 14:185–197. [PubMed: 17701466]
12. Sciarretta, KL.; Gordon, DJ.; Meredith, SC. Amyloid, prions, and other protein aggregates, Part C. In: Kheterpal, I.; Wetzel, R., editors. *Methods in enzymology.* Vol. vol. 413. Academic; New York: 2006. p. 273-312.
13. Burkoth TS, Benzinger TLS, Jones DNM, Hallenga K, Meredith SC, Lynn DG. C-terminal PEG blocks the irreversible step in β -amyloid(10–35) fibrillogenesis. *J. Am. Chem. Soc.* 1998; 120:7655–7656.
14. Pallitto MM, Ghanta J, Heinzelmann P, Kiessling LL, Murphy RM. Recognition sequence design for peptidyl modulators of β -amyloid aggregation and toxicity. *Biochemistry.* 1999; 38:3570–3578. [PubMed: 10090743]
15. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. β -sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. *Nat. Med.* 1998; 4:822–826. [PubMed: 9662374]
16. Permanne B, Adessi C, Fraga S, Frossard MJ, Saborio GP, Soto CJ. Are β -sheet breaker peptides dissolving the therapeutic problem of Alzheimer's disease? *J. Neural Transm. Suppl.* 2002:293–301. [PubMed: 12456072]
17. Gordon DJ, Sciarretta KL, Meredith SC. Inhibition of β -amyloid(40) fibrillogenesis and disassembly of β -amyloid(40) fibrils by short β -amyloid congeners containing N-methyl amino acids at alternate residues. *Biochemistry.* 2001; 40:8237–8245. [PubMed: 11444969]
18. Gordon DJ, Tappe R, Meredith SC. Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits A β 1–40 fibrillogenesis. *J. Pept. Res.* 2002; 60:37–55. [PubMed: 12081625]
19. Kokkoni N, Stott K, Amijee H, Mason JM, Doig AJ. N-Methylated peptide inhibitors of β -amyloid aggregation and toxicity: optimization of the inhibitor structure. *Biochemistry.* 2006; 45:9906–9918. [PubMed: 16893191]
20. Etienne MA, Aucoin JP, Fu Y, McCarley RL, Hammer RP. Stoichiometric inhibition of amyloid β -protein aggregation with peptides containing alternating α,α -disubstituted amino acids. *J. Am. Chem. Soc.* 2006; 128:3522–3523. [PubMed: 16536517]
21. Tjernberg LO, Lilliehook C, Callaway DJE, Naslund J, Hahne S, Thyberg J, Terenius L, Nordstedt C. Controlling amyloid β -peptide fibril formation with protease-stable ligands. *J. Biol. Chem.* 1997; 272:12601–12605. [PubMed: 9139713]

22. Chalifour RJ, McLaughlin RW, Lavoie L, Morissette C, Tremblay N, Boule M, Sarazin P, Stea D, Lacombe D, Tremblay P, Gervais FJ. Stereoselective interactions of peptide inhibitors with the β -amyloid peptide. *J. Biol. Chem.* 2003; 278:34874–34881. [PubMed: 12840031]
23. Walsh DM, Selkoe DJ. A β oligomers – a decade of discovery. *J. Neurochem.* 2007; 101:1172–1184. [PubMed: 17286590]
24. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. *Ann. Neurol.* 1999; 46:860–866. [PubMed: 10589538]
25. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. *Am. J. Pathol.* 1999; 155:853–862. [PubMed: 10487842]
26. Roher AE, Chaney MO, Kuo Y-M, Webster SD, Stine WB, Haverkamp LJ, Woods AS, Cotter RJ, Tuohy JM, Krafft GA, Bonnell BS, Emmerling MR. Morphology and toxicity of Abeta(1–42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. *J. Biol. Chem.* 1996; 271:20631–20635. [PubMed: 8702810]
27. Enya M, Morishima-Kawashima M, Yoshimura M, Shinkai Y, Kusui K, Khan K, Games D, Schenk D, Sugihara S, Yamaguchi H, Ihara Y. Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. *Am. J. Pathol.* 1999; 154:271–279. [PubMed: 9916941]
28. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. *Ann. Neurol.* 1991; 30:572–580. [PubMed: 1789684]
29. Walsh D, Klyubin I, Fadeeva J, William K, Cullen W, Anwyl R, Wolfe M, Rowan M, Selkoe D. Naturally secreted oligomers of the Alzheimer amyloid beta-protein potently inhibit hippocampal long-term potentiation in vivo. *Nature.* 2002; 416:535–539. [PubMed: 11932745]
30. Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, Agnaf OE, Hartley DM, Selkoe DJ. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. *J. Neurosci.* 2005; 25:2455–2462. [PubMed: 15758153]
31. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid β -protein on hippocampal synaptic plasticity: a potent role for trimers. *J. Physiol.* 2006; 572:477–492. [PubMed: 16469784]
32. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. *Nat. Neurosci.* 2005; 8:79–84. [PubMed: 15608634]
33. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid beta-protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. *J. Neurosci.* 2007; 27:2866–2875. [PubMed: 17360908]
34. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid- β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat. Med.* 2008; 14:837–842. [PubMed: 18568035]
35. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ. Amyloid β protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. *J. Neurosci.* 2008; 28:4231–4237. [PubMed: 18417702]
36. Necula M, Kaye R, Milton S, Glabe CG. Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct. *J. Biol. Chem.* 2007; 282:10311–10324. [PubMed: 17284452]
37. Hilbich C, Kisters-Woike B, Masters CL, Beyreuther K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease β A4 peptides. *J. Mol. Biol.* 1992; 228:460–473. [PubMed: 1453457]

38. Wood SJ, Wetzel R, Martin JD, Hurler MR. Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β /A4. *Biochemistry*. 1995; 34:724–730. [PubMed: 7827029]
39. Esler WP, Stimson ER, Ghilardi JR, Lu YA, Felix AM, Vinters HV, Mantyh PW, Lee JP, Maggio JE. Point substitution in the central hydrophobic cluster of a human beta-amyloid congener disrupts peptide folding and abolishes plaque competence. *Biochemistry*. 1996; 35:13914–13921. [PubMed: 8909288]
40. Tjernberg LO, Naslund J, Lindquist F, Johansson J, Karlstrom AR, Thyberg J, Terenius L, Nordstedt C. Arrest of β -amyloid fibril formation by a pentapeptide ligand. *J. Biol. Chem.* 1996; 271:8545–8549. [PubMed: 8621479]
41. Lowe TL, Strzelec A, Kiessling LL, Murphy RM. Structure-function relationships for inhibitors of β -amyloid toxicity containing the recognition sequence KLVFF. *Biochemistry*. 2001; 40:7882–7889. [PubMed: 11425316]
42. Kim JR, Murphy RM. Mechanism of accelerated assembly of β -amyloid filaments into fibrils by KLVFFK₆. *Biophys. J.* 2004; 86:3194–3203. [PubMed: 15111432]
43. Moss MA, Nichols MR, Reed DK, Hoh JH, Rosenberry TL. The peptide KLVFF-K₆ promotes β -amyloid(1–40) protofibril growth by association but does not alter protofibril effects on cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). *Mol. Pharmacol.* 2003; 64:1160–1168. [PubMed: 14573766]
44. Barrow CJ, Zagorski MG. Solution structures of β peptide and its constituent fragments: relation to amyloid deposition. *Science*. 1991; 253:179–182. [PubMed: 1853202]
45. Snyder SW, Lador US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, Huffaker HJ, Krafft GA, Holzman TF. Amyloid- β aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. *Biophys. J.* 1994; 67:1216–1228. [PubMed: 7811936]
46. Wood SJ, Maleeff B, Hart T, Wetzel R. Physical, morphological, and functional differences between pH 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide A β . *J. Mol. Biol.* 1996; 256:870–877. [PubMed: 8601838]
47. Klug GMJA, Losic D, Subasinghe SS, Aguilar M-I, Martin LL, Small DH. β -amyloid protein oligomers induced by metal ions and acid pH are distinct from those generated by slow spontaneous aging at neutral pH. *Eur. J. Biochem.* 2003; 270:4282–4293. [PubMed: 14622293]
48. Mantyh PW, Ghilardi JR, Rogers S, DeMaster E, Allen CJ, Stimson ER, Maggio JE. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of β -amyloid peptide. *J. Neurochem.* 1993; 61:1171–1174. [PubMed: 8360682]
49. Bush AI, Pettingell WH, Multhaup G, d'Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE. Rapid induction of Alzheimer A beta amyloid formation by zinc. *Science*. 1994; 265:1464–1467. [PubMed: 8073293]
50. Dukes KD, Rodenberg CF, Lammi RK. Monitoring the earliest amyloid- β oligomers via quantized photobleaching of dye-labeled peptides. *Anal. Biochem.* 2008; 382:29–34. [PubMed: 18694719]
51. Kaether C, Schmitt S, Willem M, Haass C. Amyloid precursor protein and notch intracellular domains are generated after transport of their precursors to the cell surface. *Traffic*. 2006; 7:408–415. [PubMed: 16536739]
52. Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K. Alzheimer's disease β -amyloid peptides are released in association with exosomes. *Proc. Natl. Acad. Sci. USA*. 2006; 103:11172–11177. [PubMed: 16837572]
53. Molina JA, Jimenez-Jimenez FJ, Aguilar MV, Meseguer I, Matos-Vega CJ, Gonzalez-Munoz MJ, de Bustos F, Porta J, Orti-Pareja M, Zurdo M, Barrios E, Martinez-Para MC. Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. *J. Neural Transm.* 1998; 105:479–488. [PubMed: 9720975]
54. Assaf SY, Chung SH. Release of endogenous zinc(2+) from brain tissue during activity. *Nature*. 1984; 308:734–736. [PubMed: 6717566]
55. Howell GA, Welch M, Frederickson CJ. Stimulation-induced uptake and release of zinc in hippocampal slices. *Nature*. 1984; 308:736–738. [PubMed: 6717567]
56. Deshpande A, Kawai H, Metharate R, Glabe CG, Busciglio J. A role for synaptic zinc in activity-dependent A β oligomer formation and accumulation at excitatory synapses. *J. Neurosci.* 2009; 29:4004–4015. [PubMed: 19339596]

57. Ding H, Wong PT, Lee EL, Gafni A, Steel DG. Determination of the oligomer size of amyloidogenic protein β -amyloid(1–40) by single-molecule spectroscopy. *Biophys. J.* 2009; 97:912–921. [PubMed: 19651050]
58. Shoji M, Gold TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai XD, McKay DM, Tintner R, Frangione B, Younkin SG. Production of the Alzheimer amyloid β protein by normal proteolytic processing. *Science.* 1992; 258:126–129. [PubMed: 1439760]
59. Guo, A.; Zhu, X-Y. Functional protein microarrays in drug discovery. In: Predki, P., editor. *Drug discovery series*. Vol. vol. 8. CRC Press; Boca Raton, FL: 2007. p. 53-71.
60. Abe K, Kaya S, Hayashi Y, Imagawa T, Kikumoto M, Oiwa K, Katoh T, Yazawa M, Taniguchi K. Correlation between the activities and the oligomeric forms of pig gastric H/K-ATPase. *Biochemistry.* 2003; 42:15132–15138. [PubMed: 14690423]
61. Guo, A.; Microsurfaces, Inc.. Personal communication.
62. Ha T, Enderle T, Chemla DS, Selvin PR, Weiss S. Quantum jumps of single molecules at room temperature. *Chem. Phys. Lett.* 1997; 271:1–5.
63. Xie SX, Trautman JK. Optical studies of single molecules at room temperature. *Annu. Rev. Phys. Chem.* 1998; 49:441–480. [PubMed: 15012434]
64. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid β -protein ($A\beta$) assembly: $A\beta$ 40 and $A\beta$ 42 oligomerize through distinct pathways. *Proc. Natl. Acad. Sci. USA.* 2003; 100:330–335. [PubMed: 12506200]
65. Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R. A structural model for Alzheimer's β -amyloid fibrils based on experimental constraints from solid state NMR. *Proc. Natl. Acad. Sci. USA.* 2002; 99:16742–16747. [PubMed: 12481027]
66. Kent A, Jha AK, Fitzgerald JE, Freed KF. Benchmarking implicit solvent folding simulations of the amyloid β (10–35) fragment. *J. Phys. Chem. B.* 2008; 112:6175–6186. [PubMed: 18348560]
67. Urbanc B, Cruz L, Ding F, Sammond D, Khare S, Buldyrev SV, Stanley HE, Dokholyan NV. Molecular dynamics simulation of amyloid- β dimer formation. *Biophys. J.* 2004; 87:2310–2321. [PubMed: 15454432]
68. Jang S, Shin S. Computational study on the structural diversity of amyloid beta peptide ($A\beta$ _{10–35}) oligomers. *J. Phys. Chem. B.* 2008; 112:3479–3484. [PubMed: 18303879]
69. Dulin F, Callebaut I, Colloc'h N, Mornon J-P. Sequence-based modeling of $A\beta$ 42 soluble oligomers. *Biopolymers.* 2007; 85:422–437. [PubMed: 17211889]
70. Prior R, D'Urso D, Frank R, Prikulis I, Cleven S, Ihl R, Pavlakovic G. Selective binding of soluble Abeta1–40 and Abeta1–42 to a subset of senile plaques. *Am. J. Pathol.* 1996; 148:1749–1756. [PubMed: 8669461]
71. Fulop L, Penke B, Zarandi M. Synthesis and fluorescent labeling of beta-amyloid peptides. *J. Pept. Sci.* 2001; 7:397–401. [PubMed: 11548055]
72. Khandogin J, Brooks CL III. Linking folding with aggregation in Alzheimer's β -amyloid peptides. *Proc. Natl. Acad. Sci. USA.* 2007; 104:16880–16885. [PubMed: 17942695]
73. Cairo CW, Strzelec A, Murphy RM, Kiessling LK. Affinity-based inhibition of β -amyloid toxicity. *Biochemistry.* 2002; 41:8620–8629. [PubMed: 12093279]
74. Hu W-P, Chang G-L, Chen S-J, Kuo Y-M. Kinetic analysis of β -amyloid peptide aggregation induced by metal ions based on surface plasmon resonance biosensing. *J. Neurosci. Methods.* 2006; 154:190–197. [PubMed: 16457893]
75. Garai K, Sahoo B, Kaushalya K, Desai R, Maiti S. Zinc lowers amyloid- β toxicity by selectively precipitating aggregation intermediates. *Biochemistry.* 2007; 46:10655–10663. [PubMed: 17718543]
76. Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, Yoshida N, Sato K. Spheroidal aggregates of β -amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3 β . *Proc. Natl. Acad. Sci. USA.* 2003; 100:6370–6375. [PubMed: 12750461]
77. Li W, Zhang J, Su Y, Wang J, Qin M, Wang W. Effects of zinc binding on the conformational distribution of the amyloid- β peptide based on molecular dynamics simulations. *J. Phys. Chem. B.* 2007; 111:13814–13821. [PubMed: 18001084]

78. Chebaro Y, Derreumaux P. Targeting the early steps of A β 16–22 protofibril disassembly by N-methylated inhibitors: A numerical study. *Proteins*. 2009; 75:442–452. [PubMed: 18837034]
79. Soto P, Griffin MA, Shea J-E. New insights into the mechanism of Alzheimer amyloid- β fibrillogenesis inhibition by N-methylated peptides. *Biophys. J.* 2007; 93:3015–3025. [PubMed: 17631541]

**Figure 1.**

Peptide inhibitors. A) Sequence of A β 40 with residues numbered. (FA β B has a carboxyfluorescein (FAM) dye covalently bound to the N-terminus and a Lys-Biotin moiety attached to the C-terminus.) Amino acids 16–21 (boxed) comprise the central hydrophobic core that inhibitors are designed to recognize. The hydrophobic residues in this region are shown underlined in bold, both here and in each inhibitor sequence below. The net charge of each inhibitor at pH 7 is also listed for comparison. For these sequences, charges are largely unchanged in the range from pH 5.8 to 7.4. B) KLVFF-K₆ employs a (primarily hydrophobic) KLVFF recognition element identical in sequence to A β 16–20 and a hydrophilic disrupting element comprised of six Lys residues [14]. C) AMY-1 is an analogue of KLVFF-K₆ that incorporates alternating α,α -disubstituted amino acids diisobutyl-, dibenzyl- and dipropyl-glycine (Dibg, Dbzg, and Dpg) on one face of the peptide [20]. D) A β 16–22m is derived from A β 16–22 and employs alternating *N*-methyl amino acids (NMeL, NMeF, NMeA) on one face of the peptide [17]. It has a hydrophobic core with charged terminal residues. E) iA β 5 is a pentapeptide designed around A β 17–21 that uses Pro to disrupt β -structure. It is primarily hydrophobic with charged Asp incorporated to improve solubility [15].





Figure 2.

Single-oligomer spectroscopy. A) Light (488 nm) from a Kr-Ar laser is focused to a diffraction-limited spot by the objective of an inverted fluorescence microscope. A nanopositioning stage scans the sample over the laser, which excites individual surface-tethered peptide species. Fluorescence is collected by the objective, filtered by dichroic (D) and notch (N) filters to remove laser light, and detected by an avalanche photodiode (APD) detector. B) During laser excitation, a monomer exhibits one characteristic fluorescence intensity (broadened by shot noise) until irreversible photobleaching occurs, returning the measured intensity to background levels. C) A dimer displays two distinct intensity levels above background. Initially, laser excitation results in fluorescence from both dyes, until one photobleaches, causing a discrete drop in measured intensity. Photobleaching of the second dye results in a return to background intensities.

**Figure 3.**

Inhibition of acid-promoted oligomerization (pH 5.8). Each distribution represents at least 100 small FAβB species from multiple samples, interrogated one at a time. The total percentage of monomer and each oligomer observed (up to $n = 5$) is plotted in order to facilitate comparison between different sample environments; each sample additionally contains ~2–7% larger oligomers, not shown. A) As we have reported previously [50], acidic pH (black bars) significantly shifts the distribution of FAβB monomers and oligomers toward larger species, as compared to samples at pH 7.4 (white bars). B) The presence of ten molar equivalents of any inhibitor at pH 5.8 significantly shifts the distribution of FAβB species toward monomers, as compared to inhibitor-free samples (pH 5.8, Panel A). AMY-1 is most successful in producing monomers of FAβB. *Inset:* The most successful inhibitors AMY-1 and Aβ16–22m were tested at concentrations equimolar with FAβB. Under these conditions, the resulting distributions are statistically indistinguishable.




Figure 4.

Inhibition of zinc-promoted oligomerization at pH 7.4. Each distribution represents at least 100 small FAβB species from multiple samples, interrogated one at a time. The total percentage of monomer and each oligomer observed (up to $n = 5$) is plotted in order to facilitate comparison between different sample environments; each sample additionally contains ~1–5% larger oligomers, not shown. A) As we have reported previously [50], the presence of 4 equivalents of Zn²⁺ (black bars) significantly shifts the distribution of FAβB monomers and oligomers toward larger species, as compared to nominally metal-free samples at pH 7.4 (white bars). B) The addition of ten molar equivalents of any inhibitor to samples containing 4 equivalents of Zn²⁺ (pH 7.4) significantly shifts the distribution of FAβB species toward monomers, as compared to inhibitor-free samples (Panel A). Aβ16–22m and KLVFF-K₆ are most successful in producing monomers of FAβB. *Inset:* Aβ16–22m and KLVFF-K₆ were tested at concentrations equimolar with FAβB. Each successfully shifts the distribution of FAβB species toward monomers at this reduced concentration; as was observed for 10 equivalents of inhibitor, the two distributions are statistically indistinguishable.